Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | DGKA | P23743 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23501478 | 0.82 | KDM4E (0.42) | LMNADGKAKDM4EDUSP3MEN1 | |
| SCHEMBL6988086 | 0.81 | TSHR (0.43) | USP2LMNACYP3A4MAPTSMN1; SMN2 | |
| SCHEMBL2733536 | 0.81 | LMNA (0.53) | USP2LMNACYP3A4MAPTSMN1; SMN2 | |
| SCHEMBL7188584 | 0.79 | KDM4E (0.51) | USP2LMNAMAPTDGKAKDM4E | |
| SCHEMBL18918226 | 0.79 | KDM4E (0.51) | LMNAMAPTDGKAKDM4EDUSP3 | |
| SCHEMBL25252748 | 0.78 | CA1 (0.39) | USP2LMNACYP3A4MAPTSMN1; SMN2 | |
| SCHEMBL12504631 | 0.77 | LMNA (0.40) | LMNADGKAKDM4EDUSP3MEN1 | |
| SCHEMBL8901869 | 0.77 | KDM4E (0.57) | USP2LMNAMAPTDGKAKDM4E | |
| SCHEMBL728980 | 0.76 | ALDH1A1 (0.35) | USP2LMNACYP3A4MAPTSMN1; SMN2 | |
| SCHEMBL10908830 | 0.75 | TSHR (0.41) | LMNACYP3A4SMN1; SMN2DGKAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070265460-A1 | PROCESS FOR THE PRODUCTION OF (TRIMETHYLSILYLOXY)SILYLALKYLGLYCEROL METHACRYLATES | JOHNSON & JOHNSON VISION CARE INC. | 2007-11-15 | — | — | US | disclosed |
| EP-1791848-A1 | PROCESS FOR THE PRODUCTION OF (TRIMETHYLSILYLOXY)SILYLALKYLGLYCEROL METHACRYLATES | Johnson and Johnson Vision Care, Inc. (US) | 2007-06-06 | — | — | EP | disclosed |
| WO-2006026245-A1 | PROCESS FOR THE PRODUCTION OF (TRIMETHYLSILYLOXY)SILYLALKYLGLYCEROL METHACRYLATES | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2006-03-09 | — | — | WO | disclosed |
| US-20060047134-A1 | Process for the production of (trimethylsilyloxy)silylalkylglycerol methacrylates | JOHNSON & JOHNSON VISION CARE INC. | 2006-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265460-A1 | PROCESS FOR THE PRODUCTION OF (TRIMETHYLSILYLOXY)SILYLALKYLGLYCEROL METHACRYLATES | SGMS2, SGMS1, SMS | USP2 2402/4885LMNA 2463/4885CYP3A4 1044/4885 |
| US-20060047134-A1 | Process for the production of (trimethylsilyloxy)silylalkylglycerol methacrylates | SGMS2, SGMS1, SMS | USP2 2402/4885LMNA 2463/4885CYP3A4 1044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.